ES2377772T3 - Derivados de piperidina como agonistas de receptores muscarínicos - Google Patents

Derivados de piperidina como agonistas de receptores muscarínicos Download PDF

Info

Publication number
ES2377772T3
ES2377772T3 ES08806636T ES08806636T ES2377772T3 ES 2377772 T3 ES2377772 T3 ES 2377772T3 ES 08806636 T ES08806636 T ES 08806636T ES 08806636 T ES08806636 T ES 08806636T ES 2377772 T3 ES2377772 T3 ES 2377772T3
Authority
ES
Spain
Prior art keywords
alkyl
piperidyl
hexahydro
alkoxy
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08806636T
Other languages
English (en)
Spanish (es)
Inventor
Yun-Xing Cheng
Xuehong Luo
Vijayaratnam Santhakumar
Miroslaw Jerzy Tomaszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2377772T3 publication Critical patent/ES2377772T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES08806636T 2007-09-11 2008-09-09 Derivados de piperidina como agonistas de receptores muscarínicos Active ES2377772T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97128807P 2007-09-11 2007-09-11
US971288P 2007-09-11
PCT/GB2008/050802 WO2009034380A1 (en) 2007-09-11 2008-09-09 Piperidine derivatives as agonists of muscarinic receptors

Publications (1)

Publication Number Publication Date
ES2377772T3 true ES2377772T3 (es) 2012-03-30

Family

ID=40011174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08806636T Active ES2377772T3 (es) 2007-09-11 2008-09-09 Derivados de piperidina como agonistas de receptores muscarínicos

Country Status (18)

Country Link
US (1) US8119661B2 (enExample)
EP (1) EP2197843B1 (enExample)
JP (1) JP2010539151A (enExample)
KR (1) KR20100052528A (enExample)
CN (1) CN101874020B (enExample)
AR (1) AR071245A1 (enExample)
AT (1) ATE539056T1 (enExample)
AU (1) AU2008299604A1 (enExample)
BR (1) BRPI0816331A2 (enExample)
CA (1) CA2699286A1 (enExample)
CL (1) CL2008002689A1 (enExample)
ES (1) ES2377772T3 (enExample)
MX (1) MX2010002584A (enExample)
PE (1) PE20091090A1 (enExample)
RU (1) RU2010110036A (enExample)
TW (1) TW200924766A (enExample)
UY (1) UY31334A1 (enExample)
WO (1) WO2009034380A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
CN105189482A (zh) 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
GB2519470A (en) * 2013-09-18 2015-04-22 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic M1 receptor agonists
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
EP0786997A4 (en) 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
US5756508A (en) 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
AU7528696A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ES2175925T3 (es) 1998-01-19 2002-11-16 Pfizer Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
PT1975164E (pt) 2001-04-18 2010-04-20 Euro Celtique Sa Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
DE60319813T2 (de) 2002-04-18 2009-04-23 Schering Corporation 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
CA2488845A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
DE602004008762T2 (de) 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
WO2005042517A2 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
EP1937670A1 (en) 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2009034380A1 (en) 2009-03-19
TW200924766A (en) 2009-06-16
KR20100052528A (ko) 2010-05-19
PE20091090A1 (es) 2009-08-27
US20090076078A1 (en) 2009-03-19
ATE539056T1 (de) 2012-01-15
AU2008299604A1 (en) 2009-03-19
BRPI0816331A2 (pt) 2015-04-14
CL2008002689A1 (es) 2009-11-27
RU2010110036A (ru) 2011-10-20
CN101874020B (zh) 2012-11-07
JP2010539151A (ja) 2010-12-16
AR071245A1 (es) 2010-06-09
MX2010002584A (es) 2010-03-26
UY31334A1 (es) 2009-04-30
EP2197843A1 (en) 2010-06-23
US8119661B2 (en) 2012-02-21
CN101874020A (zh) 2010-10-27
EP2197843B1 (en) 2011-12-28
CA2699286A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
EP2197843B1 (en) Piperidine derivatives as agonists of muscarinic receptors
AU2007256014B2 (en) Muscarinic receptor agonists that are effective in the treatment of pain, Alzheimer's disease and schizophrenia
US20090221567A1 (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
BRPI0712331A2 (pt) composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor, de mal de alzheimer, de esquizofrenia, de ansiedade e de depressão, em um animal de sangue quente, e, processo para preparar um composto
WO2009110844A1 (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof
MX2010011841A (es) Agonistas del receptor muscarinico utiles en el tratamiento del dolor, enfermedad de alzheimer y esquizofrenia.